NEU 1.03% $19.30 neuren pharmaceuticals limited

Ann: Q4 2021 quarterly activity and cash flow report, page-8

  1. 1,079 Posts.
    lightbulb Created with Sketch. 448
    A tidy quarterly from Neuren. Cash reserves are ample, quarterly expenses very minimal, potential is burgeoning. And I appreciate Neuren keeping staffing costs down in lieu of any significant upscale to the business. No shenanigans here.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.